Quick Answer
Cardlytics, Inc. reported Research And Development Expense of $39.77 million for the year ending 2025.
- Cardlytics, Inc. showed a decrease of -19.8% in Research And Development Expense from 2024 to 2025.
- This data is from Cardlytics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $3.01 million | Q2 2017: $3.09 million | Q3 2017: $3.42 million | Q1 2018: $3.46 million | Q2 2018: $4.89 million | Q3 2018: $4.10 million | Q1 2019: $2.94 million | Q2 2019: $2.78 million | Q3 2019: $3.02 million | Q1 2020: $3.85 million | Q2 2020: $3.97 million | Q3 2020: $4.63 million | Q1 2021: $6.22 million | Q2 2021: $8.93 million | Q3 2021: $11.14 million | Q1 2022: $12.29 million | Q2 2022: $13.58 million | Q3 2022: $13.76 million | Q1 2023: $11.56 million | Q2 2023: $14.85 million | Q3 2023: $12.43 million | Q1 2024: $13.05 million | Q2 2024: $13.47 million | Q3 2024: $13.19 million | Q1 2025: $11.71 million | Q2 2025: $11.30 million | Q3 2025: $8.80 million.
- Over the full 10 years of available data (2016 to 2025), Cardlytics, Inc.'s Research And Development Expense has grown by 186.0%.
- Historical annual values: Fiscal year 2025: $39.77 million | Fiscal year 2024: $49.61 million | Fiscal year 2023: $51.35 million | Fiscal year 2022: $54.44 million | Fiscal year 2021: $38.10 million | Fiscal year 2020: $17.53 million | Fiscal year 2019: $11.70 million | Fiscal year 2018: $16.21 million | Fiscal year 2017: $12.15 million | Fiscal year 2016: $13.90 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: